Surgical Science Sweden AB (publ)
SUSRF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.28 | 0.57 | -5.59 | -3.65 |
| FCF Yield | -0.33% | 0.05% | -0.25% | 0.54% |
| EV / EBITDA | 149.08 | -297.56 | 236.72 | 190.90 |
| Quality | ||||
| ROIC | 0.42% | -0.54% | 0.37% | 0.69% |
| Gross Margin | 64.64% | 65.21% | 68.85% | 67.61% |
| Cash Conversion Ratio | -0.16 | -0.72 | -0.21 | 1.45 |
| Growth | ||||
| Revenue 3-Year CAGR | 2.49% | 1.56% | 2.75% | 3.28% |
| Free Cash Flow Growth | -521.70% | 123.16% | -135.14% | 365.72% |
| Safety | ||||
| Net Debt / EBITDA | -21.86 | 27.18 | -25.53 | -18.73 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.46 | 0.35 | 0.42 | 0.45 |
| Cash Conversion Cycle | 306.34 | 377.32 | 327.35 | 233.37 |